Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
bevacizumab + ofranergene obadenovec
- Development stage
- Discontinued
- Lead developer
- VBL Therapeutics
- Modality
- Gene Therapies, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
Combination therapy consisting of bevacizumab (Avastin), an anti-VEGF monoclonal antibody, and ofranergene obadenovec (VB-111), a novel anticancer viral therapy. Ofranergene obadenovec utilizes a proprietary Vascular Targeting System to target tumor vasculature and induce cell death in angiogenic endothelial cells while also triggering an anti-tumor immune response with CD8 T-cell recruitment.
- Brand names
- Avastin + VB-111
- Other names
- ofra-vec + bevacizumab
02
Targets
Beyond the preview
Go deeper on bevacizumab + ofranergene obadenovec.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on bevacizumab + ofranergene obadenovec.